Search Results

You are looking at 11 - 20 of 28 items for :

  • GHD in adults x
  • User-accessible content x
Clear All
Open access

Alessandro Ciresi, Stefano Radellini, Valentina Guarnotta, Maria Grazia Mineo, and Carla Giordano

demonstrated in GHD adults, to date, very few studies about gender difference are available in prepubertal GHD children. The aim of this study was to evaluate the impact of gender on the clinical and metabolic parameters in a large series of prepubertal GHD

Open access

Anita Hokken-Koelega, Aart-Jan van der Lely, Berthold Hauffa, Gabriele Häusler, Gudmundur Johannsson, Mohamad Maghnie, Jesús Argente, Jean DeSchepper, Helena Gleeson, John W Gregory, Charlotte Höybye, Fahrettin Keleştimur, Anton Luger, Hermann L Müller, Sebastian Neggers, Vera Popovic-Brkic, Eleonora Porcu, Lars Sävendahl, Stephen Shalet, Bessie Spiliotis, and Maithé Tauber

with CO-GHD. Small-group breakout sessions also permitted discovery and discussion of uncovered perceptions about the role of paediatric vs adult endocrinologists in managing transition patients. Materials and methods A total of 130 delegates

Open access

Pinaki Dutta, Bhuvanesh Mahendran, K Shrinivas Reddy, Jasmina Ahluwalia, Kim Vaiphei, Rakesh K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, Viral N Shah, Girish Parthan, and Anil Bhansali

QoL without any change in coagulation parameters following 6 months of r-hGH therapy in acromegaly patients with GHD. The short-term GH replacement is not associated with tumor re-growth and colonic epithelial changes. GHD in adults is characterized by

Open access

Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen, and on behalf of the Growth Hormone Research Society

therapy At the time when a patient reaches adult height, GHD is either reconfirmed by retesting or recognised as a life-long condition based on the underlying pathology. Since growth can no longer be used as a biomarker, the clinical focus in patients

Open access

Taísa A R Vicente, Ívina E S Rocha, Roberto Salvatori, Carla R P Oliveira, Rossana M C Pereira, Anita H O Souza, Viviane C Campos, Elenilde G Santos, Rachel D C Araújo Diniz, Eugênia H O Valença, Carlos C Epitácio-Pereira, Mario C P Oliveira, Andrea Mari, and Manuel H Aguiar-Oliveira

percentage fat mass, and contrary to what has been reported in adult-onset GHD (AOGHD), does not cause insulin resistance. We hypothesize that the difference in IS (increased in our IGHD individuals and reduced in AOGHD individuals) is probably caused by

Open access

Marko Stojanovic, Zida Wu, Craig E Stiles, Dragana Miljic, Ivan Soldatovic, Sandra Pekic, Mirjana Doknic, Milan Petakov, Vera Popovic, Christian Strasburger, and Márta Korbonits

-secreted with GH. We have aimed to study the correlation of constitutive and dynamic AIP and GH secretion using in vivo human models of normal GH secretion, patients with GH deficiency (GHD) and patients with GH hypersecretion – acromegaly. Subjects and

Open access

María Dolores Rodríguez Arnao, Amparo Rodríguez Sánchez, Ignacio Díez López, Joaquín Ramírez Fernández, Jose Antonio Bermúdez de la Vega, Diego Yeste Fernández, María Chueca Guindulain, Raquel Corripio Collado, Jacobo Pérez Sánchez, Ana Fernández González, and ECOS Spain Study Collaborative Investigator Group

pathologies) and in sensitivity to the hormone ( 4 ). Treatment with r-hGH has been shown to be effective in children and adolescents with GHD, increasing short-term growth and adult height ( 5 , 6 ). GH therapy requires daily subcutaneous injections for long

Open access

H A Booij, W D C Gaykema, K A J Kuijpers, M J M Pouwels, and H M den Hertog

.01) Worse quality of life EuroQoL-5D visual analog scale, P  = 0.03 Quality of Life Assessment of GHD in adults, P  = 0.01 Giuliano, 2016 ( 19 ) Cross-sectional 48, TBI Complicated mild TBI (GCS 13–15) 1 and 5 years 1 year: any degree NR

Open access

Anastasia P Athanasoulia-Kaspar, Matthias K Auer, Günter K Stalla, and Mira Jakovcevski

, high doses of glucocorticoid substitution therapy and older age at diagnosis are the most consistently identified risk factors associated with increased morbidity and mortality ( 18 , 19 ). In addition, growth hormone deficiency (GHD) has been linked

Open access

Urszula Smyczyńska, Joanna Smyczyńska, Maciej Hilczer, Renata Stawerska, Ryszard Tadeusiewicz, and Andrzej Lewiński

Introduction Growth hormone (GH) therapy is widely approved in children with short stature caused by GH deficiency (GHD). It has also been documented that GH therapy may be beneficial in children with idiopathic short stature (ISS); however